Scarborough Advisors’s Clearside Biomedical CLSD Stock Holding History

Scarborough Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18	Closed	-$324	–	439
2023 Q4	$324	Buy	+18	New	+$257	﹤0.01%	674

Other funds holding CLSD

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Scarborough Advisors's CLSD Position: Q1 2024 in Review

Scarborough Advisors sold out of Clearside Biomedical (CLSD) in Q1 2024, closing a stake of 18 shares — an estimated $324 sold.

Scarborough Advisors first reported a position in CLSD in Q4 2023 and held it in 1 quarter. The position peaked at $324 in Q4 2023. 51 funds tracked by Wall St. Rank hold CLSD as of Q1 2024.

Scarborough Advisors reported no remaining Clearside Biomedical position as of Q1 2024 after selling out during the quarter.
Scarborough Advisors sold 18 Clearside Biomedical shares in Q1 2024, an estimated $324.
Scarborough Advisors first reported a position in Clearside Biomedical in Q4 2023 and held it in 1 quarter.
Scarborough Advisors's Clearside Biomedical position peaked at $324 in Q4 2023.
51 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2024.

Based on Scarborough Advisors's 13F filing for Q1 2024, filed 10 May 2024.